Is Amphastar Pharmaceuticals (AMPH) Cheap After Its Recent Share Price Rebound?
Amphastar Pharmaceuticals (AMPH) stock has drawn investor attention after recent share price moves, including a gain over the past month and past 3 months, set against the backdrop of its branded and generic injectable and inhalation portfolio.
At a latest share price of $23.18, Amphastar Pharmaceuticals has seen short term momentum build, with a 30 day share price return of 14.53% and a 90 day share price return of 17.43%. This comes even as the year to date share price return is down 12.40% and the 1 year total shareholder return is down 21.21%, pointing to improving sentiment recently after a weaker longer term experience for shareholders.
Compare Amphastar Pharmaceuticals' recent rebound with other stocks showing similar price and fundamentals momentum by scanning the hand picked 47 high quality undervalued stocks.
After a stronger few months but a weaker recent year, Amphastar Pharmaceuticals now sits at a crossroads. Should investors pay a premium for the recent momentum, or wait and look for a potentially cheaper entry point based on valuation?
Most Popular Narrative: 1.5% Overvalued
On the latest data, Amphastar Pharmaceuticals closed at $23.18, compared with a widely followed fair value narrative of about $22.83, which leaves only a small implied premium in the current price.
The analysts have a consensus price target of $22.83 for Amphastar Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $30.0, and the most bearish reporting a price target of just $19.0.
Read the complete narrative. Read the complete narrative.
The fair value story for Amphastar Pharmaceuticals rests on a mix of modest revenue growth, lower future margins, and a different earnings multiple than today. It explores which of those assumptions most affects the valuation and how much earnings power the narrative incorporates by 2029.
Result: Fair Value of $22.83 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Amphastar Pharmaceuticals could challenge this overvaluation view if its expanding U.S. manufacturing base improves resilience or if the diversified pipeline delivers approvals that reduce product concentration risk.
Find out about the key risks to this Amphastar Pharmaceuticals narrative.
Another View on Amphastar Pharmaceuticals Valuation
The analyst narrative suggests Amphastar Pharmaceuticals is slightly overvalued against a fair value of $22.83. Yet on simple P/E math the picture looks different. The stock trades at about 12.6x earnings, compared with a fair ratio of 14.5x and a US Pharmaceuticals industry average of 16.3x. That gap points to a cheaper entry price than both the fair ratio and peers. This raises the question of whether the real risk is that expectations are too low rather than too high.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mix of caution and optimism around Amphastar Pharmaceuticals, it makes sense to review the full picture for yourself and move quickly while sentiment is still shifting. To see both sides of the story in one place, start with these 3 key rewards and 3 important warning signs.
Looking for more Amphastar Pharmaceuticals investment ideas?
If Amphastar Pharmaceuticals has your attention, do not stop here. Use the Simply Wall Street Screener to quickly surface other focused opportunities before the crowd catches on.
- Target resilient cash generators with healthy balance sheets by reviewing the list of solid balance sheet and fundamentals (52 results).
- Spot potential value opportunities ahead of others by scanning the 47 high quality undervalued stocks.
- Build a steadier income stream by checking companies in the 11 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com